Danziger Asaf 4

Accession 0001645113-23-000007

CIK 0001645113other

View on SEC.gov Company Profile

Filed

Jan 8, 7:00 PM ET

Accepted

Jan 9, 6:18 PM ET

Size

30.6 KB

Accession

0001645113-23-000007

Insider Transaction Report

Form 4

Period: 2023-01-05

NovoCure LtdNVCR

Danziger Asaf

Director

Transactions

Exercise/Conversion
Ordinary Shares
2023-01-05$11.46/sh+25,000$286,500→ 38,583 total
Sale
Ordinary Shares
2023-01-05$115.21/sh−3,702$426,512→ 19,944 total
Sale
Ordinary Shares
2023-01-05$116.06/sh−1,395$161,906→ 18,549 total
Sale
Ordinary Shares
2023-01-05$118.47/sh−2,123$251,515→ 15,427 total
Sale
Ordinary Shares
2023-01-05$108.00/sh−187,500$20,250,000→ 13,583 total
Sale
Ordinary Shares
2023-01-05$111.23/sh−8,369$930,916→ 30,214 total
Sale
Ordinary Shares
2023-01-05$119.99/sh−500$59,994→ 13,583 total
Sale
Ordinary Shares
2023-01-05$119.35/sh−1,344$160,405→ 14,083 total
Exercise/Conversion
Ordinary Shares
2023-01-05$7.15/sh+187,500$1,340,625→ 201,083 total
Award
Ordinary Shares
2023-01-06$62.30/sh+39$2,430→ 13,622 total
Sale
Ordinary Shares
2023-01-05$112.86/sh−2,000$225,726→ 28,214 total
Sale
Ordinary Shares
2023-01-05$114.35/sh−4,568$522,362→ 23,646 total
Sale
Ordinary Shares
2023-01-05$117.01/sh−999$116,894→ 17,550 total
Exercise/Conversion
Options to Buy Ordinary Shares
2023-01-05−25,000→ 0 total
Exercise: $11.46Exp: 2026-02-24→ Ordinary Shares (25,000 underlying)
Exercise/Conversion
Options to Buy Ordinary Shares
2023-01-05−187,500→ 0 total
Exercise: $7.15Exp: 2027-02-22→ Ordinary Shares (187,500 underlying)

Footnotes (12)

[F1]Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger.
[F10]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 500 shares in multiple trades at prices ranging from $119.98 to $120.00. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F11]In accordance with the issuer's Employee Share Purchase Plan, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022.
[F12]Fully vested as of the date hereof.
[F2]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 8,369 shares in multiple trades at prices ranging from $111.00 to $111.97. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F3]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,000 shares in multiple trades at prices ranging from $112.29 to $113.26. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F4]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,568 shares in multiple trades at prices ranging from $113.76 to $114.75. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F5]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 3,702 shares in multiple trades at prices ranging from $114.79 to $115.78. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F6]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,395 shares in multiple trades at prices ranging from $115.79 to $116.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F7]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 999 shares in multiple trades at prices ranging from $116.85 to $117.82. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F8]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,123 shares in multiple trades at prices ranging from $117.91 to $118.90. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
[F9]On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,344 shares in multiple trades at prices ranging from $118.95 to $119.84. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file

4
wf-form4_167330630889022.xmlPrimary
FORM 4

Issuer

NovoCure Ltd

CIK 0001645113

→

Entity typeother

Related Parties

filerCIK 0001654435

Filing Metadata

Form type: 4
Filed: Jan 8, 7:00 PM ET
Accepted: Jan 9, 6:18 PM ET
Size: 30.6 KB

View on SEC.gov